resTORbio (NASDAQ:TORC) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

resTORbio (NASDAQ:TORC) posted its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.07, MarketWatch Earnings reports.

NASDAQ TORC opened at $2.49 on Friday. The company has a market cap of $90.75 million, a PE ratio of -1.38 and a beta of 2.59. resTORbio has a 52 week low of $0.86 and a 52 week high of $11.36. The firm’s 50-day simple moving average is $2.34 and its two-hundred day simple moving average is $1.69.

TORC has been the subject of several research reports. Evercore ISI upgraded shares of resTORbio from an “in-line” rating to an “outperform” rating and increased their price target for the company from $2.00 to $4.00 in a research report on Wednesday, April 29th. Zacks Investment Research upgraded shares of resTORbio from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research report on Thursday, June 18th. Finally, FIG Partners restated a “reduce” rating on shares of resTORbio in a research report on Thursday, May 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. resTORbio presently has a consensus rating of “Hold” and a consensus target price of $3.17.

About resTORbio

resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.

See Also: Using other technical indicators with support levels

Earnings History for resTORbio (NASDAQ:TORC)

Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with's FREE daily email newsletter.